CETUXIMAB(CAS: 205923-56-4)

Cetuximab is a monoclonal antibody with a molecular weight of approximately 145 kDa. It is a protein that is typically produced in a crystalline form. Cetuximab has a low solubility in water and is relatively stable. It does not react with common inorganic acids or bases but may be susceptible to degradation under harsh conditions. Its stability and solubility make it suitable for pharmaceutical applications.

Cetuximab is synthesized through a complex process involving hybridoma technology. The antibody is produced in mammalian cells, such as Chinese hamster ovary (CHO) cells. The production process includes cell culture, antibody purification, and formulation. The yield is relatively high, and the method ensures high selectivity and purity.

Cetuximab is primarily used in the pharmaceutical industry, particularly in oncology. It is used as a targeted therapy for treating certain types of cancer, such as colorectal cancer and squamous cell carcinoma. Additionally, research into its applications in other areas, such as biosensors and drug delivery systems, is ongoing.

Proper handling of cetuximab requires the use of personal protective equipment (PPE) such as gloves and lab coats. It should be handled in a well-ventilated area, preferably in a fume hood. In case of a spill, it should be cleaned up carefully using appropriate absorbent materials. For more detailed safety information, refer to the safety data sheet (SDS) for cetuximab.